Currently, there are several published or ongoing clinical trials that demonstrated beneficent effects of mesenchymal stem cell-based therapy in the treatment of chronic ischemic cardiomyopathy. Injection of mesenchymal stem cells attenuated fibrosis, induced neo-angiogenesis, enhanced concractility, and improved the quality of life of patients with chronic ischemic cardiomyopathy and implanted cardioverter defibrillator. Haack-Sorensen and co-workers performed demonstrated that intra-myocardial injections of autologous  mesenchymal stem cell significantly improve quality of life, physical limitations and angina stability of patients with chronic coronary artery diseases and refractory angina.